AADI BIOSCIENCE INC (AADI)
US00032Q1040 - Common Stock
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...
AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024
AADI stock results show that Aadi Bioscience missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for...
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for...
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
Aadi Bioscience files for $150M mixed shelf (NASDAQ:AADI)
Aadi Bioscience files a prospectus for a mixed shelf offering of up to $150M, but it is not an offer to sell these securities.
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...
FSLR Stock Alert: First Solar Scores New ‘Buy’ Rating
First Solar stock is rising on Friday as investors in FSLR react to a new "buy" rating and $211 price target from Jefferies.
Why Is Mangoceuticals (MGRX) Stock Down 33% Today?
Mangoceuticals stock is falling on Friday after the company put into effect a public offering for shares of MGRX.
Why Is Aadi Bioscience (AADI) Stock Down 56% Today?
Aadi Bioscience stock is taking a beating on Friday as investors in AADI react negatively to interim data from a clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today!
Aadi Bioscience stock plunges 57% on study data for anti-tumor drug (AADI)
Aadi BioScience (AADI) shares plunged 57% after-hours following disappointing results from a registrational study for its anti-tumor drug nab-sirolimus. Read more here.
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...
Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...